<http://schema.org/headline>
"Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fiercebiotech.com/press-releases/boehringer-ingelheim-receives-fda-priority-review-afatinib-treat-egfr-mutat>